SARS-CoV-2 structural antigen (None universally established; individual proteins have abbreviations (S, E, M, N))

SARS-CoV-2 structural antigens refer collectively to the four major proteins forming the coronavirus particle: spike glycoprotein (S), membrane (M), envelope (E), and nucleocapsid (N) proteins[3][5]. The spike protein is responsible for receptor binding (ACE2), host cell entry, and is the principal antigenic target for vaccines and most neutralizing antibodies[1][2][3][4][5]. The nucleocapsid protein packages the viral RNA genome and contributes to immune recognition. Membrane and envelope proteins play roles in viral assembly, morphogenesis, and pathogenesis. These antigens are highly conserved among coronaviruses but undergo frequent mutations, especially the spike protein, influencing viral infectivity and immune evasion[1][2][5]. Their structural and antigenic properties make them central to therapeutic intervention, vaccine design, and diagnostic development for COVID-19.

Other names

SARS-CoV-2 spike glycoprotein (S protein)SARS-CoV-2 membrane glycoprotein (M protein)SARS-CoV-2 envelope protein (E protein)SARS-CoV-2 nucleocapsid protein (N protein)Coronavirus structural proteinsCOVID-19 viral antigensSARS2 structural proteins

Neutralizing antibodies: block spike-ACE2 interaction, preventing viral entry Vaccine-induced immunity: generate anti-spike and anti-nucleocapsid antibodies, some neutralizing and T cell-mediated Fusion inhibition: interfere with spike conformational changes Diagnostic: antibody/antigen detection for infection monitoring